Literature DB >> 20565433

Morbidity in 303 first-episode bipolar I disorder patients.

Ross J Baldessarini1, Paola Salvatore, Hari-Mandir Kaur Khalsa, Priscilla Gebre-Medhin, Harkaitz Imaz, Ana González-Pinto, Jesus Perez, Núria Cruz, Carlo Maggini, Mauricio Tohen.   

Abstract

OBJECTIVES: To test the hypotheses that: (i) depressive-dysthymic-dysphoric (D-type) morbidity is more prevalent than manic-hypomanic-psychotic (M-type) morbidity even from first episodes of bipolar I disorder (BPD-I) and despite treatment; (ii) initial presentations predict later morbidity; (iii) morbidity varies internationally; and (iv) early and later morbidity are similar.
METHODS: We followed SCID-based, DSM-IV BPD-I patients (n = 303) systematically and prospectively for two years to estimate the percent of weeks in specific morbid states from first lifetime major episodes.
RESULTS: Total morbidity accounted for 44% of the first two years, and D-type exceeded M-type illnesses by 2.1-fold (30%/14%) among morbidities ranking: mixed states (major + minor) >or= dysthymia >or= mania >or= major depression > hypomania > psychosis. In 164 cases, morbidities at 0.5-2.5 and 2.5-4.5 years were very similar. Depressive or mixed initial episodes predicted a 3.6-fold excess of D-type morbidity, and initial M-type episodes predicted a 7.1-fold excess of M-type morbidity over two years. Morbidity in European (EU) sites was nearly half that in the U.S., and 22% greater overall among men than women. In five comparable studies, illness accounted for 54% of follow-up time, and the ratio of D/M morbidity averaged 3.0.
CONCLUSIONS: In accord with four midcourse studies, morbidity from BPD-I onset, despite treatment by community standards, averaged 44%, was 68% D-type morbidity, and was strongly predicted by first-episode polarity. Lower morbidity in EU than U.S. sites may reflect differences in healthcare or social systems.

Entities:  

Mesh:

Year:  2010        PMID: 20565433     DOI: 10.1111/j.1399-5618.2010.00812.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  23 in total

Review 1.  Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments.

Authors:  Michael W Jann
Journal:  Am Health Drug Benefits       Date:  2014-12

2.  Dissimilar morbidity following initial mania versus mixed-states in type-I bipolar disorder.

Authors:  Ross J Baldessarini; Paola Salvatore; Hari-Mandir Kaur Khalsa; Mauricio Tohen
Journal:  J Affect Disord       Date:  2010-04-27       Impact factor: 4.839

3.  Age at onset versus family history and clinical outcomes in 1,665 international bipolar-I disorder patients.

Authors:  Ross J Baldessarini; Leonardo Tondo; Gustavo H Vazquez; Juan Undurraga; Lorenza Bolzani; Aysegul Yildiz; Hari-Mandir K Khalsa; Massimo Lai; Beatrice Lepri; Maria Lolich; Pier Mario Maffei; Paola Salvatore; Gianni L Faedda; Eduard Vieta; Mauricio Tohen
Journal:  World Psychiatry       Date:  2012-02       Impact factor: 49.548

Review 4.  Distinguishing between unipolar depression and bipolar depression: current and future clinical and neuroimaging perspectives.

Authors:  Jorge Renner Cardoso de Almeida; Mary Louise Phillips
Journal:  Biol Psychiatry       Date:  2012-07-10       Impact factor: 13.382

Review 5.  Memantine: New prospective in bipolar disorder treatment.

Authors:  Giulia Serra; Francesca Demontis; Francesca Serra; Lavinia De Chiara; Andrea Spoto; Paolo Girardi; Giulio Vidotto; Gino Serra
Journal:  World J Psychiatry       Date:  2014-12-22

Review 6.  Options for pharmacological treatment of refractory bipolar depression.

Authors:  Leonardo Tondo; Gustavo H Vázquez; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2014-02       Impact factor: 5.285

Review 7.  Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment.

Authors:  Leonardo Tondo; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2016-09       Impact factor: 5.285

8.  Affective instability and the course of bipolar depression: results from the STEP-BD randomised controlled trial of psychosocial treatment.

Authors:  Jonathan P Stange; Louisa G Sylvia; Pedro Vieira da Silva Magalhães; David J Miklowitz; Michael W Otto; Ellen Frank; Christine Yim; Michael Berk; Darin D Dougherty; Andrew A Nierenberg; Thilo Deckersbach
Journal:  Br J Psychiatry       Date:  2016-01-21       Impact factor: 9.319

9.  Extreme attributions predict the course of bipolar depression: results from the STEP-BD randomized controlled trial of psychosocial treatment.

Authors:  Jonathan P Stange; Louisa G Sylvia; Pedro Vieira da Silva Magalhães; David J Miklowitz; Michael W Otto; Ellen Frank; Michael Berk; Andrew A Nierenberg; Thilo Deckersbach
Journal:  J Clin Psychiatry       Date:  2013-03       Impact factor: 4.384

Review 10.  Bipolar disorder diagnosis: challenges and future directions.

Authors:  Mary L Phillips; David J Kupfer
Journal:  Lancet       Date:  2013-05-11       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.